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A B S T R A C T
Intravenous drug use (IVDU) remains a major
means of hepatitis C virus (HCV) transmission. In
this study, 101 drug users were studied prospec-
tively after cessation of IVDU. Of these, 75.8%
were anti-HCV positive, and 71.4% had elevated
levels of alanine aminotransferase. These levels
decreased significantly within 1 month of IVDU
cessation (p 0.02). Liver biopsies showed minimal
or mild fibrosis in 32 (71%) of 45 subjects, and
severe fibrosis in two (4.4%) subjects. Anti-HCV-
positive intravenous drug users in this study
presented with mild liver disease and variable
stages of disease progression. Biochemical disease
activity might be affected by IVDU.
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Following the introduction of blood donor screen-
ing for hepatitis C virus (HCV) infection, intra-
venous drug use (IVDU) remains the major mode
of HCV transmission in developed countries [1].
Anti-HCV prevalence in Germany is c. 1% in
blood donors [2] and 70–80% in intravenous drug
(IVD) users [3]. Currently, there are c. 150 000
HCV-infected IVD users in Germany, and the
number is increasing by c. 10 000 each year [4].
Little is known about the natural course of HCV
infection in IVD users. In patients with post-
transfusion HCV infection, histopathological
alterations appear to be more severe [5]. The
present study aimed to provide prospective data
on anti-HCV prevalence and viraemia in a group
of recently injecting IVD users, and to correlate
these with data regarding alanine aminotransf-
erase (ALT) levels and histopathogical changes.
The study followed a group of 101 consecutive
drug users (91 IVDU; ten non-IVDU) from an in-
patient clinic for drug addicts in Freiburg, Ger-
many, between January 1997 and July 1998. The
mean follow-up period was 8 months (range 2–18
months). After informed written consent was
obtained, each patient was interviewed by means of
a standardised questionnaire to obtain the data listed
in Table 1. All participants had consumed drugs
until 2–3 weeks before entering the clinic. Screen-
ing for continued alcohol or drug consumptionwas
performed through blood and urine tests. Patients
continuing to use drugs or alcohol were excluded
from the study and discharged from the clinic.
All subjects were tested for HCV, hepatitis B
virus (HBV), hepatitis A virus (HAV) and human
immunodeficiency virus (HIV). Sera were tested
for the presence of anti-HCV with a fourth-
generation anti-HCV assay (Monolisa; Sanofi
Diagnostics Pasteur, Marnes-la-Coquette, France)
and a recombinant immunoblot assay (Recomblot;
Table 1. Clinical and serological data of patients in the
study group
Total drug users
n = 101
IVD users
n = 91
Non-IVD users
n = 10
Age, years (mean ± SD) 27.3 ± 5.1
Women 16 (15.8%)
Duration of IVDU NA 5.6 ± 4.4 NA
History of
Jaundice 30 (29.7%) 30 (33.0%) 0
Blood transfusions 2 (2.0%) 2 (2.2%) 0
Tattoos 64 (64.6%) 61 (67.0%) 3 (30.0%)
Hepatomegaly None None None
Anti-HIV1-positive 2 (2.0%)a 2 (2.2%) 0
Anti-HAV-positive 30 (29.7%) 27 (29.7%) 3 (30.0%)
Anti-HBc-positive 43 (42.6%) 42 (46.2%) 1 (10.0%)
HBsAg-positive 4 (4.0%)b 4 (4.4%) 0
Anti-HCV-positive 70 (69.3%)c 69 (75.8%) 1 (10%)
aIncludes one anti-HCV and one anti-HCV ⁄HBsAg-positive subject.
bThree of four had been co-infected with HCV in the absence of HBV DNA.
cIncludes three HBsAg-positive subjects.
IVDU, intravenous drug use; NA, not applicable.
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Mikrogen, Martinsried, Germany). A commer-
cially available ELISA was used to detect anti-
HAV, anti-HBV core (HBc) antigen, HBV surface
antigen (HBsAg) and anti-HIV (Sorin Biomedica
Diagnostics, Saluggia Vercelli, Italy). Serum sam-
ples of 70 anti-HCV-positive subjects were tested
for HCV RNA with the Amplicor PCR assay
(Hoffman La Roche, Basel, Switzerland).
Results ofmatchedALT tests at 1, 6 and14 weeks
were available for 41 patients. Liver biopsies were
obtained from 45 anti-HCV positive subjects with
elevated ALT levels. One of the patients was
positive for HBsAg. The histomorphological gra-
ding and staging was based on the classification
systemofHytiroglou et al. [6].Descriptive statistics
were obtained for all numerical (mean ± standard
deviation) and categorical (relative frequencies)
variables (SPSS software; SPSS Inc., Chicago, IL,
USA). Statistical significance was evaluated by the
Student t-test for paired numerical variables and
the chi-square test for categorical variables, with
p < 0.05 considered to be significant.
Table 1 summarises the clinical and serological
findings in the study population. None of the
individuals had jaundice or hepatomegaly. Of the
101 subjects, 70 were anti-HCV-positive, and three
also had HBsAg. Anti-HCV positivity correlated
with the duration of IVDU; thus 31 (66%) of 47
subjects who had been IVD users for < 4 years, and
18 (95%) of 19 subjects who had been IVD users for
> 8 years, were anti-HCV-positive. The mean viral
load was 3.7 · 106 RNA-equivalents ⁄mL. Geno-
type 3 was most frequent (47.3%), followed by
genotypes 1a (30.5%) and 1b (11.1%). More than
one genotype was found in five patients. ALT
levels were elevated in 52 (57.2%) of 91 IVD users,
but were normal in all ten non-IVD users. Of 67
anti-HCV-positive ⁄HBsAg-negative subjects, 47
(70%) had increased ALT levels. These ALT levels
decreased significantly after follow-up periods of
6 and 14 weeks (mean ALT 34.8 ± 14.4 vs. 26.5 ±
11.4 U ⁄L; p 0.02). The histological activity index
was stage 0 in two patients (4.4%), stage 1 in 34
(74%) and stage 2 in ten (22.2%). Minimal-to-mild
fibrosis (stage 0 ⁄ 1) was present in 32 (71%)
patients, moderate fibrosis (stage 2) in 13 (29%),
and severe fibrosis in two (4.4%), with one of the
last-mentioned patients being HBsAg-positive.
Liver cirrhosis was not found. Neither the histo-
logical activity index nor the extent of fibrosis
correlated with ALT levels after 6 weeks or the
duration of IVDU.
Persistent HCV infection may be present in up
to 98% of IVD users, and is associated with
duration of drug use [1,3,7–9]. Despite this high
prevalence, only two prospective studies that
compare histopathological and biochemical find-
ings in these patients have been published [10,11].
In the present series, the prevalence of HCV was
70% and correlated with the duration of IVDU.
Elevated ALT levels are used to select HCV-
infected patients for liver biopsy and treatment.
However, they are poor indicators of the extent of
liver cell damage in post-transfusion HCV infec-
tion [12]. In the present study, 17% of anti-HCV-
negative IVD users had elevated ALT levels at
initial evaluation, while 13% of anti-HCV-posit-
ive subjects had normal results. ALT levels did
not correlate with histopathological grade and
stage, although previous studies showed positive
and negative correlations [10,11,13]. Interestingly,
ALT levels decreased significantly within 6 weeks
after discontinuation of parenteral drug use, but
no further decrease occurred thereafter. As a
consequence, elevated ALT levels in recent IVD
users, and even histopathological alterations,
might reflect not only HCV infection, but also
non-specific changes secondary to toxic sub-
stances injected with drugs, or concomitant viral
or bacterial infections. This should be taken into
account when interpreting liver histology or liver
function tests in active IVD users.
Histopathological liver changes in anti-HCV-
positive IVD users are generally mild and highly
variable [5,10,14,15]. The duration of IVDU in the
present study did not correlate with histopatho-
logical grade and stage, reflecting inter-individual
variability in disease progression.
In conclusion, the present study found that
anti-HCV-positive IVD users usually present with
mild liver disease. Active IVD use may cause
increases in serum ALT levels independent of
HCV infection, and might also affect histopatho-
logical findings. Additional follow-up data on the
time course of HCV-related liver disease in IVD
users, including sequential biopsies, are needed to
characterise the progression of the disease and to
identify prognostic factors.
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A B S T R A C T
The modes of infection and transmission of
Pneumocystis jiroveci remain unclear. This study
explored the relationship between the incidence
of infection and climatic factors. In total, 536 cases
of P. jiroveci infection were identified in the period
1994–1998, with an inverse correlation between
the incidence of Pneumocystis pneumonia and the
minimum mean ambient temperature (Spearman
correlation coefficient: r ) 0.30; p 0.02; ARIMA
model: r ) 0.250, p 0.07). The highest number of
cases occurred in winter (ANOVA test, p < 0.05),
and there was a clear season-related incidence of
P. jiroveci infection.
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Pneumocystis jiroveci, known previously as Pneu-
mocystis carinii f. sp. hominis [1], is an atypical
fungus that causes pneumonia in immunocom-
promised individuals. Despite the high prevalence
of P. jiroveci pneumonia (PCP) in such patients,
little is known about the epidemiology and modes
of transmission of this infection [2]. Generally,
PCP is considered to result from acquisition
de novo rather than reactivation of latent infection,
but inter-human transmission has been reported
[3,4]. If the air-borne infection hypothesis is
correct, the epidemiological pattern of P. jiroveci
infection could be similar to that observed for
other infectious respiratory illnesses, which have a
higher incidence in the colder months. The aim of
this study was to explore potential relationships
between the incidence of P. jiroveci infection and
different climatic factors in order to investigate the
possible seasonality of the infection.
All cases of P. jiroveci infection diagnosed from
January 1994 until December 1998 at the Virgen
del Rocı´o University Hospital, Seville, Spain were
reviewed retrospectively. This tertiary referral
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